The gut-adherent microbiota of PSC–IBD is distinct to that of IBD

Quraishi, Mohammed Nabil; Sergeant, Martin J.; Kay, Gemma L.; Iqbal, Tariq; Chan, Jacqueline; Constantinidou, Chrystala; Trivedi, Palak; Ferguson, James; Adams, David H.; Pallen, Mark J.; Hirschfield, Gideon M.

doi:10.1136/gutjnl-2016-311915

Cited by 144 publications

(123 citation statements)

References 4 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…The presumed involvement of the gut–liver axis in disease pathogenesis1 has prompted investigations into mucosal2 and faecal intestinal microbiota composition, as has been reported by Kummen et al 3 in this journal. Microbiota as diagnostic biomarkers of disease are of interest from the clinician’s point of view and Kummen et al 3 have suggested a panel of taxa and even a single genus ( Veillonella ) with a reasonable diagnostic accuracy differentiating PSC and healthy controls (HCs).…”

mentioning

confidence: 72%

Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis

Rühlemann

Heinsen

Zenouzi

et al. 2016

Gut

View full text Add to dashboard Cite

mentioning

confidence: 72%

Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis

Rühlemann

Heinsen

Zenouzi

et al. 2016

Gut

View full text Add to dashboard Cite

“…This contrasts data from mucosal microbiota in PSC, as highlighted by a recent letter in this journal by Quraishi et al 3 As this letter shows, the results of four independent (but smaller) studies of gut mucosal microbiota in PSC are highly heterogeneous 3 4. This may have been caused by inherent variability of biopsy sampling, site and local status of inflammation when using mucosal biopsies.…”

mentioning

confidence: 81%

“…The differences between the studies could be related to severity of liver disease, differences related to the UC control cohort, or other unknown factors. Still, Veillonella has been observed in several diseases associated with fibrosis and could potentially influence disease progression 2 3…”

mentioning

confidence: 99%

Response to ‘Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis’ by Rühlemannet al

Kummen

Hov

2016

Gut

View full text Add to dashboard Cite

“…[8][9][10] Recently, studies using next-generation sequencing have reported a distinct fecal or mucosal microbiota composition in PSC-IBD patients. [11][12][13][14][15][16][17][18] There is a close interplay between gut flora and BA metabolism. Besides their role in nutrient absorption and lipid digestion, BAs are important signaling molecules, acting in inflammation and metabolism, through activation of BA receptors such as the G-protein-coupled BA transmembrane receptor TGR5, and the nuclear BA receptor Farnesoid X receptor (FXR).…”

Section: Introductionmentioning

confidence: 99%

The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease

Torres

Palmela

Brito

et al. 2017

United European Gastroenterology Journal

View full text Add to dashboard Cite

Background: Patients with primary sclerosing cholangitis associated with inflammatory bowel disease (PSC-IBD) have a very high risk of developing colorectal neoplasia. Alterations in the gut microbiota and/or gut bile acids could account for the increase in this risk. However, no studies have yet investigated the net result of cholestasis and a potentially altered bile acid pool interacting with a dysbiotic gut flora in the inflamed colon of PSC-IBD. Aim: The aim of this study was to compare the gut microbiota and stool bile acid profiles, as well as and their correlation in patients with PSC-IBD and inflammatory bowel disease alone. Methods: Thirty patients with extensive colitis (15 with concomitant primary sclerosing cholangitis) were prospectively recruited and fresh stool samples were collected. The microbiota composition in stool was profiled using bacterial 16S rRNA sequencing. Stool bile acids were assessed by high-performance liquid chromatography tandem mass spectrometry. Results: The total stool bile acid pool was significantly reduced in PSC-IBD. Although no major differences were observed in the individual bile acid species in stool, their overall combination allowed a good separation between PSC-IBD and inflammatory bowel disease. Compared with inflammatory bowel disease alone, PSC-IBD patients demonstrated a different gut microbiota composition with enrichment in Ruminococcus and Fusobacterium genus compared with inflammatory bowel disease. At the operational taxonomic unit level major shifts were observed within the Firmicutes (73%) and Bacteroidetes phyla (17%). Specific microbiota-bile acid correlations were observed in PSC-IBD, where 12% of the operational taxonomic units strongly correlated with stool bile acids, compared with only 0.4% in non-PSC-IBD. Conclusions: Patients with PSC-IBD had distinct microbiota and microbiota-stool bile acid correlations as compared with inflammatory bowel disease. Whether these changes are associated with, or may predispose to, an increased risk of colorectal neoplasia needs to be further clarified.

show abstract

The gut-adherent microbiota of PSC–IBD is distinct to that of IBD

Cited by 144 publications

References 4 publications

Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis

Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis

Response to ‘Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis’ by Rühlemannet al

The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease

Contact Info

Product

Resources

About